GlaxoSmithKline is set to unveil plans to launch late-stage clinical trials on 10 new drugs over the next two years, the Telegraph reported, without citing sources.
The new drugs, which have not been detailed to investors, will include cancer and respiratory disease medicines, the newspaper said on its website.
The venture arm of GlaxoSmithKline joined investors in ZappRx, a prescription app, in a second instance recently of big pharma putting cash into a mobile health firm.
ZappRx announced it had closed a $1 million round from backers led by current investor Atlas Venture but also including GSK-backed SR One.
The round follows $1 million invested by Atlas Venture in September 2013.
The 2014 SBIR and STTR Omnibus Grant Solicitation of the NIH is now live and the National Cancer Institute’s (NCI) budget for the program is increasing. Funding from the NCI Small Business Innovation Research & Small Business Tech Transfer (SBIR & STTR) Programs can help you advance your technology towards commercialization and can also help spark investor interest in your business.
The next application due date is April 5, 2014. We encourage you to start preparing your application and are happy to provide feedback on your project. If you’d like to take advantage of this opportunity, please email the NCI SBIR program director listed in your relevant technology area. Also be sure to check that all of your required registrations are complete. It’s never too early to start the registration process.
Directing a child to set up a diagnostic test is one way to illustrate the ease of using a device. That’s the approach Biomeme took for its pitch on crowdfunding website AngeList. Biomeme co-founder Max Perelman’s cute-as-a-button 7-year-old daughter takes on the role of lab assistant.
The DreamIt Health Philadelphia graduate developed a test kit to identify the DNA or RNA signature of bacteria and viruses through blood, urine or saliva samples. The company raised about $1 million in a mix of debt and options, according to a Form D filing with the U.S. Securities and Exchange Commission, and received $400,000 from the Philadelphia area division of Ben Franklin Technology Partners, the economic investment arm for Pennsylvania.
Getting specialty medications can be a big hassle. Dozens of pages of forms are required. Patients rely on call centers to find out the status of their prescriptions, and can go days wondering exactly when the next refill is coming. What if you could handle it all, instead, with just a few clicks on a smartphone app?
That’s the kind of thing ZappRx, a recently-formed startup out of Cambridge, MA, is trying to do.
The statistics surrounding startup success are pretty daunting — in fact, of the 500,000+ businesses owners that launched companies in 2012, only a handful will ever achieve a fraction of the notoriety of famed CEOs like Zuckerberg, Dorsey or Karp.
When launching a startup, there are countless decisions to consider: number of founders, sources of funding, location and target market, to name a few.
This infographic takes a look at the statistics surrounding startups and examines how many of them actually manage to get off the ground.
Baltimore is known for being home to companies such as Under Armour Inc. (NYSE:UA) and McCormick & Co. (NYSE:MKC) and, of course, HBO’s “The Wire.” But a new survey suggests Baltimore also is a destination for high-salaried technology workers.
Baltimore in 2013 had the second-highest average salary for employees in the technology sector, according to jobs database Dice.com. The 2013 average salary for tech workers was $97,588 — a 0.3 percent decrease from the year before.
ROCK SPRING VENTURES,A LEADING EARLY-STAGE LIFE SCIENCE VENTURE CAPITAL FUND, IS NOW EPIDAREX CAPITAL
Our new name is inspired by Epidaurus, the home of ancient Greece’s first hospital and the temple of the Greek God of Medicine. It reflects our focus on innovation in the healthcare sector and our commitment to investing in young life science and health technology companies. Visit www.epidarex.com.
STAY TUNED FOR A NUMBER OF EXCITING ANNOUNCEMENTS THROUGHOUT THE COMING YEAR…
Johnson & Johnson ($JNJ) is the latest Big Pharma company that has vowed to open its clinical trial data vaults to the public. Going a step further than previous efforts, it’s enlisting the help of Yale University to manage data requests.
Under an agreement with the Yale School of Medicine, the school’s Open Data Access (YODA) Project will serve as an independent body to oversee requests from investigators and physicians looking to access anonymized clinical trial data from J&J’s Janssen. YODA, not J&J, will review each request and make final decisions on data sharing. Members of the YODA team will select and appoint an independent external panel of non-Janssen experts to help in some cases to assess requests.
Emergent BioSolutions Inc. announced today the closing of its previously announced offering of 2.875% Convertible Senior Notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. Emergent issued $250 million aggregate principal amount of its notes, which includes the additional $35 million principal amount of notes purchased by the initial purchasers under the exercise of the option granted to them by the company.
Emergent intends to use a majority of the net proceeds from the offering to finance the acquisition of Cangene Corporation, announced in December 2013. The company intends to use any remaining net proceeds from the offering for general corporate purposes, which may include repaying outstanding indebtedness under its existing credit facility.
